

1600

RAW SEQUENCE LISTING

(A 222B

DATE: 08/23/2004

PATENT APPLICATION: US/09/454,223B

TIME: 10:39:22

- 1 <110> APPLICANT: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
- 2 KORNBLUTH, Richard S.
- 3 <120> TITLE OF INVENTION: MULTIMERIC FUSION PROTEINS OF THE SUPERFAMILY LIGANDS (AMENDED)
 - 4 <130> FILE REFERENCE: UCSD1590
 - 5 <140> CURRENT APPLICATION NUMBER: US/09/454,223B
 - 6 <141> CURRENT FILING DATE: 1999-12-09
 - 7 <150> PRIOR APPLICATION NUMBER: US 60/111,471
 - 8 <151> PRIOR FILING DATE: 1998-12-09
 - 9 <160> NUMBER OF SEQ ID NOS: 22
 - 10 <170> SOFTWARE: PatentIn version 3.1
 - 12 <210> SEQ ID NO: 1
 - 13 <211> LENGTH: 1552
 - 14 <212> TYPE: DNA
 - 15 <213> ORGANISM: Artificial Sequence
 - 16 <220> FEATURE:
 - 17 <223> OTHER INFORMATION: Murine surfactant protein D (without the CRD) fused to the
 - 18 extracellular portion of human CD40L
 - 19 <220> FEATURE:
 - 20 <221> NAME/KEY: 5'UTR
 - 21 <222> LOCATION: (7)..(31)
 - 22 <220> FEATURE:
 - 23 <221> NAME/KEY: CDS
 - 24 <222> LOCATION: (32)..(1444)
 - 25 <220> FEATURE:
 - 26 <221> NAME/KEY: sig_peptide
 - 27 <222> LOCATION: (32)..(88)
 - 28 <223> OTHER INFORMATION: Signal peptide from murine surfactant protein D
 - 29 <220> FEATURE:
 - 30 <221> NAME/KEY: misc feature
 - 31 <222> LOCATION: (88)..(799)
 - 32 <223> OTHER INFORMATION: Mature murine surfactant protein D including hub region,
 - 33 collagenous portion, and neck, but excluding carbohydrate
 - 34 recognition domain (CRD)
 - 35 <220> FEATURE:
 - 36 <221> NAME/KEY: misc feature
 - 37 <222> LOCATION: (801)..(1546)
 - 38 <223> OTHER INFORMATION: Human CD40 ligand extracellular region, including stalk.
 - 39 <300> PUBLICATION INFORMATION:
 - 40 <301> AUTHORs: Motwani M
 - 41 <302> TITLE: Mouse surfactant protein-D. cDNA cloning, characterization, and
 - 42 gene localization to chromosome 14.
 - 43 <303> JOURNAL: J. Immunol.
 - 44 <304> VOLUME: 155



RAW SEQUENCE LISTING DATE: 08/23/2004 PATENT APPLICATION:. US/09/454,223B TIME: 10:39:22

45	<305>	ISSU	JE: 1	L2														
46	<306>	PAGE	ES: 5	671	TO !	5677												
47	<307>	DATE	2: 19	95														
48	<313>	RELI	EVANT	r RES	SIDUI	ES:	(32).	(80	02)									
49	<300>	PUBI	PUBLICATION INFORMATION:															
50	<301>	AUTI	AUTHORs: Spriggs MK															
51	<302>	TITLE: Recombinant human CD40 ligand stimulates B cell proliferation and																
52		immu	immunoglobulin E secretion															
53	<303>	JOUE	RNAL:	: Joi	ırna:	l of	Expe	erime	ental	l Med	dicir	ıe						
54	<304>	VOL	JME:	176														
55	<305>	ISSU	ISSUE: 6															
56	<306>	PAGES: 1543-1550																
57	<307>	DATE: 1992																
58	<313>	RELEVANT RESIDUES: (803)(1552)																
59	<400>	SEQU	SEQUENCE: 1															
60		gcta	agcga	aat t	cca	ccago	ga ag	gcaat	ctga	a c a	atg o	etg (ccc t	ctt (ctc 1	ccc a	atg	52
61		_						-	_	1	Met I	Leu I	Pro 1	Phe 1	Leu S	Ser N	Met	
62										:	l.				5			
63		ctt	gtc	ttg	ctt	gta	cag	CCC	ctg	gga	aat	ctg	gga	gca	gaa	atg	aag	100
64			_	_		_	_		_			_		_	_	Met	_	
65				10					15	•			_	20			_	
66		agc	ctc	tcg	cag	aqa	tca	gta	CCC	aac	acc	tgc	acc	cta	gtc	atg	tgt	148
67		_		_		_		_				_			_	Met	_	
68			25			J		30				•	35				-	
69		aqc	cca	aca	qaq	aat	qqc	ctq	cct	ggt	cqt	qat	qqa	cqq	qat	ggg	aqa	196
70		_						_			_	_			_	Gly	_	
71		40					45			-	_	50	-		_	-	55	
72	•	qaa	ggt	сса	cqq	ggt	qaq	aaq	qqt	qat	cca	ggt	ttq	cca	qqa	cct	atq	244
73		_						_		_			_			Pro	_	
74			-		Ū	60		•	_	_	65	_			_	70		
75		ggg	ctc	tca	ggg	ttg	cag	ggc	cct	aca	ggt	cca	gtt	gga	ccc	aaa	gga	292
76		Gly	Leu	Ser	Gly	Leu	Gln	Gly	Pro	Thr	Gly	Pro	Val	Gly	Pro	Lys	Gly	
77					75					80					85			
78		gag	aat	ggc	tct	gct	ggc	gaa	cct	gga	cca	aag	gga	gaa	cgt	gga	cta	340
79		Glu	Asn	Gly	Ser	Ala	Gly	Glu	Pro	Gly	Pro	Lys	Gly	Glu	Arg	Gly	Leu	
80				90					95					100				
81		agt	gga	cct	cca	gga	ctt	cca	ggt	att	cct	ggt	cca	gct	ggg	aaa	gaa	388
82		Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly	Pro	Ala	Gly	Lys	Glu	
83			105					110					115					
84		ggt	CCC	tct	ggg	aag	cag	ggg	aac	ata	gga	cct	caa	ggc	aaa	cca	ggt	436
85		Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile	Gly	Pro	Gln	Gly	Lys	Pro	Gly	
86		120					125					130					135	
87		cct	aaa	gga	gag	gct	ggg	CCC	aaa	gga	gaa	gta	ggt	gct	cct	ggc	atg	484
88		Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly	Glu	Val	Gly	Ala	Pro	Gly	Met	
89			_	_		140	_		-	-	145		_	•		150		,
90		caa	gga	tct	aca	ggg	gca	aaa	ggc	tcc	aca	ggc	CCC	aag	gga	gaa	aga	532
91		Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser	Thr	Gly	Pro	Lys	Gly	Glu	Arg	
92			-		155					160					165			
93		ggt	gcc	cct	ggt	gtg	caa	gga	gcc	cca	ggg	aat	gct	gga	gca	gca	gga	580

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/454,223B TIME: 10:39:22

DATE: 08/23/2004

94 95	Gly Al	a Pro	Gly	Val (Gln (_	Ala I 175	Pro (Gly 2	Asn .		Gly <i>I</i> 180	Ala A	Ala (Sly	
96	cct qc		cct	acc (aat (_	raa (act	cca (aaa a	aaa a	rcc	628
97	Pro Al								_							020
98	18	_	110	mia (_	190	OTIL (J	nia .		195	JCI 2	9 \	Jry 1	. 10	
99	cca go		aad	aaa (aat d	att .	cct (aga d	raa :	atc a	922	676
100		Sly Le	_		_			•			_	_				070
101	200	JIY DC	и шуб	Gry	205	71119	Ory	vul	110	210	1100	**** 9	O y	110	215	
102		gaa ag	r aaa	ctt		gac	agt	act	act		agg	caq	caq	atq		724
103		Slu Se				_	_	_	_	_		-			-	, 2 1
104	017	J_	_ 0_1	220					225		5		02	230		
105	acc t	ta aa	a qqa		cta	caq	cat	cta		att	acc	ttc	tcc		tat	772
106	-	Leu Ly				_	_			_	_					
107		1	235	-			5	240					245		- 1 -	
108	cag a	aaa gc			ttc	cct	gat		cat	aga	agg	tta	gac	aaq	ata	820
109	_	ys Al	_	_			_			_		_	_	_		
110		25					255	1		· J	,	260		4		
111	gaa c	gat ga	a agg	aat	ctt	cat	qaa	gat	ttt	qta	ttc	atq	aaa	acq	ata	868
112		Asp Gl					_	_		_		_		_		
113		265	٦			270		•			275		-			
114.	caq a	aga tg	c aac	aca	gga	gaa	aga	tcc	tta	tcc	tta	ctg	aac	tgt	gag	916
115	_	Arg Cy				_	_					_		_		
116	280				285					290		•			295	
117	gag a	att aa	a agc	cag	ttt	gaa	ggc	ttt	gtg	aag	gat	ata	atg	tta	aac	964
118	Glu I	le Ly	s Ser	Gln	Phe	Glu	Gly	Phe	Val	Lys	Asp	Ile	Met	Leu	Asn	
119				300					305					310		
120	aaa g	gag ga	g acg	aag	aaa	gaa	aac	agc	ttt	gaa	atg	caa	aaa	ggt	gat	1012
121	Lys G	Glu Gl	u Thr	Lys	Lys	Glu	Asn	Ser	Phe	Glu	Met	Gln	Lys	Gly	Asp	
122			315					320					325		•	
123	cag a	aat cc	t caa	att	gcg	gca	cat	gtc	ata	agt	gag	gcc	agc	agt	aaa	1060
124	Gln A	Asn Pr		Ile	Ala	Ala	His	Val	Ile	Ser	Glu		Ser	Ser	Lys	
125		33					335					340				
126		aca tc			_		_	_						_		1108
127		Thr Se	r Val	Leu	Gln	_	Ala	Glu	Lys	Gly	-	Tyr	Thr	Met	Ser	
128		345				350					355					
129		aac tt			_	_				_	_		_		_	1156
130		Asn Le	u Val	Thr		GIu	Asn	GLY	Lys			Thr	Val	Lys	_	
131	360				365					370		t t-			375	1004
132	-	gga ct					_		_			_			,	1204
133	Gin G	Bly Le	u Tyr	_	шe	туr	Ата	GIn			Pne	Cys	ser		Arg	
134				380					385			.		390		1050
135	-	get te			_				_	_		_		_		1252
136	GIU F	Ala Se			Ala	PIO	Pne		Ala	ser	ьeu	cys		ьуѕ	ser	
137	~~~ -		395		~	~ - -	++-	400	~~~	<u> </u>	~~-		405	~~~	244	1300
138	_	ggt ag			_				_	_	_				-	1300
139 140	PLO 6	Gly Ar 41	_	GIU	мтд	тте	1.eu	шeu	ALG	HIG	ATG	420	1111	птр	261	
140	taa			+~~	~~~	433		+ ~ ~	2++	020	++~		442	ata	+++	1348
141	_	gcc aa Ala Ly		_							_			_		1340
144	ser F	rra ny	s PIO	Cys	GTÀ	GTII	GTII	oer.	тте	птв	neu	GTÅ	сту	val	FIIC	

RAW SEQUENCE LISTING PATENT APPLICATION: US/09/454,223B DATE: 08/23/2004 TIME: 10:39:22

143	425			430					435					
144		caa cca	ggt gct		ata	ttt	atc	aat		act	gat.	cca	agc	1396
145			Gly Ala	_	_		_							
146	440	OIII IIC	445		• • • • • • • • • • • • • • • • • • • •		· ~ _	450				,	455	
147		age cat	ggc act		ttc	aca	tcc		ggc	tta	ctc	aaa		1444
148			Gly Thr											
149	GIII VAI		460	O _T y	1110	1111	465	1110	Ory	200	200	470	Lou	
150	tasacsa	tat caca	ttgcag g	ctata	rat ac	r add		ract	aaaa	arct	tc a		acade	1504
151	-	_	aattat a			_	_	_					acage	1552
153 <210>	2.9	_	auctuc a	caccc	caas	9 900	regee	-guu	0095	geace	•			1332
154 <211>														
155 <212>							·							
	ORGANISM: Artificial Sequence													
	FEATURE:													
	OTHER INFORMATION: Synthetic Construct													
	SEQUENCE: 2													
160	-		Leu Ser	Met	Len	Val	Leu	Leu	Val	Gln	Pro	Leu	Glv	
161	1	110 1110	5	1100		vul	10	1 00	* 41	01		15	0-1	
162		Glv Ala	a Glu Met	Lvs	Ser	Len		Gln	Ara	Ser	Val		Asn	
163	11011 Leu	20	· ora nec	275		25	001	O#11			30			
164	Thr Cvs		val Met	Cvs	Ser		Thr	Glu	Asn	Glv		Pro	Glv	
165	IIII Cyc	35		075	40			0_4		45			1	
166	Ara Asp		Asp Gly	Ara		Glv	Pro	Ara	Glv	Glu	Lvs	Glv	Asp	
167	50	,	,	55		1		5	60			1		
168		Leu Pro	Gly Pro		Glv	Leu	Ser	Glv		Gln	Glv	Pro	Thr	
169	65		70		1			75			- 1		80	
170		Val Gly	Pro Lys	Glv	Glu	Asn	Glv		Ala	Glv	Glu	Pro	Gly	
171			85	1			90			1		95		
172	Pro Lvs	Glv Glu	arg Gly	Leu	Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	
173	4	100	-			105			•		110	-		
174	Pro Gly	Pro Ala	a Gly Lys	Glu	Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile	
175	•	115			120			-	-	125	_			
176	Gly Pro	Gln Gly	Lys Pro	Gly	Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly	
177	130	-	_	135		_			140	_				
178	Glu Val	Gly Ala	a Pro Gly	Met	Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser	
179	145		150	þ				155					160	
180	Thr Gly	Pro Lys	s Gly Glu	Arg	Gly	Ala	Pro	Gly	Val	Gln	Gly	Ala	Pro	
181			165				170					175		
182	Gly Asn	Ala Gly	/ Ala Ala	Gly	Pro	Ala	Gly	Pro	Ala	Gly	Pro	Gln	Gly	
183		180).			185					190			
184	Ala Pro	Gly Se	Arg Gly	Pro	Pro	Gly	Leu	Lys	Gly	Asp	Arg	Gly	Val	
185		195			200					205				
186	Pro Gly	Asp Ar	Gly Ile	Lys	Gly	Glu	Ser	Gly	Leu	Pro	Asp	Ser	Ala	
187	210			215					220					
188	Ala Leu	Arg Gl	n Gln Met	Glu	Ala	Leu	Lys	Gly	Lys	Leu	Gln	Arg	Leu	
189	225		230	1				235					240	
190	Glu Val	Ala Phe	e Ser His	Tyr	Gln	Lys	Ala	Ala	Leu	Phe	Pro	Asp	Gly	
191			245				250					255		
192	His Arg	Arg Le	ı Asp Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp	

RAW SEQUENCE LISTING DATE: 08/23/2004
PATENT APPLICATION: US/09/454,223B TIME: 10:39:22

```
265
                                                                     270
    193
                           260
               Phe Val Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser
    194
                                          . 280
    195
               Leu Ser Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe
    196
    197
                                        295
    198
               Val Lys Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser
    199
                                    310
                                                        315
    200
               Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val
    201
                                                    330
               Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu
    202
    203
                           340
                                                345
    204
               Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly
     205
                                            360
               Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln
     206
     207
                                        375
               Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile
     208
     209
                                    390
               Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu
     210
     211
                               405
                                                    410
               Arq Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser
     212
     213
               Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe
     214
     215
                                            440
               Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr
     216
                                                             460
     217
                                        455
     218
               Ser Phe Gly Leu Leu Lys Leu.
     219
               465
                                    470
     221 <210> SEQ ID NO: 3
     222 <211> LENGTH: 1574
     223 <212> TYPE: DNA
     224 <213> ORGANISM: Artificial Sequence
     225 <220> FEATURE:
     226 <223> OTHER INFORMATION: Murine surfactant protein D (except CRD) fused to the
               extracellular domain of murine RANKL/TRANCE
     228 <220> FEATURE:
     229 <221> NAME/KEY: 5'UTR
     230 <222> LOCATION: (7)..(31)
     231 <220> FEATURE:
     232 <221> NAME/KEY: misc feature
     233 <222> LOCATION: (32)..(799)
     234 <223> OTHER INFORMATION: Murine surfactant protein D including hub region,
collagenous
               portion, and neck, but excluding carbohydrate recognition domain
     235
     236
               (CRD)
     237 <220> FEATURE:
     238 <221> NAME/KEY: CDS
     239 <222> LOCATION: (32)..(1534)
     240 <220> FEATURE:
     241 <221> NAME/KEY: sig_peptide
     242 <222> LOCATION: (32)..(87)
```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 08/23/2004
PATENT APPLICATION: US/09/454,223B TIME: 10:39:23

Input Set : N:\Crf4\08202004\I454223.raw
Output Set: N:\CRF4\08232004\I454223B.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 3,17,32,38
Seq#:3; Line(s) 234,246
Seq#:22; Line(s) 785

VERIFICATION SUMMARY

DATE: 08/23/2004 TIME: 10:39:23

PATENT APPLICATION: US/09/454,223B